GSK’s Stiefel begins subcutaneous ofatumumab Phase III trial for pemphigus vulgaris
British drug maker GlaxoSmithKline’s (GSK) subsidiary Stiefel has commenced Phase III trial to assess the efficacy and safety of subcutaneous ofatumumab in patients with a rare autoimmune skin disorder, pemphigus vulgaris. (Source: Drug Development Technology)
Source: Drug Development Technology - October 7, 2014 Category: Pharmaceuticals Source Type: news

How skin falls apart: Pathology of autoimmune skin disease revealed at the nanoscale
Researchers studying a rare, blistering disease have discovered new details of how autoantibodies destroy healthy cells in skin. The research has the potential to help clinicians identify who may be at risk for developing Pemphigus vulgaris (PV), an autoimmune skin disorder, by distinguishing pathogenic (disease-causing) autoimmune antibodies from other nonpathogenic autoimmune antibodies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 10, 2014 Category: Science Source Type: news

Stephen I. Katz
DirectorStephen I. Katz, M.D., Ph.D. has been Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases since August 1995 and is also a Senior Investigator in the Dermatology Branch of the National Cancer Institute. He was born in New York in 1941 and his early years were spent in the Washington, D.C., and Bethesda, Maryland areas. After attending the University of Maryland, where he graduated with honors, he graduated from the Tulane University Medical School with honors in 1966. He completed a medical internship at Los Angeles County Hospital and did his dermatology residency at the University...
Source: PHRMA - July 30, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news

Fixed-Dose Rituximab Provides Durable Remission of PemphigusFixed-Dose Rituximab Provides Durable Remission of Pemphigus
Fixed-dose rituximab therapy can produce durable remission of pemphigus, a retrospective study suggests. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 13, 2014 Category: Dermatology Tags: Dermatology News Source Type: news

GSK begins Phase III study of subcutaneous Ofatumumab to treat pemphigus vulgaris
Genmab collaborator GlaxoSmithKline (GSK) has commenced the third phase of its study of subcutaneous formulation of ofatumumab, a human monoclonal antibody, to treat an autoimmune skin disorder, pemphigus vulgaris. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2013 Category: Pharmaceuticals Source Type: news

Genetics Home Reference: benign chronic pemphigus
New topic on Genetics Home Reference (Source: NLM General Announcements)
Source: NLM General Announcements - May 30, 2013 Category: Databases & Libraries Source Type: news

Rituximab may provide functional cure for pemphigus
Rituximab can induce long-term complete remission in patients with the chronic autoimmune disease pemphigus, show study findings. (Source: MedWire News - Dermatology)
Source: MedWire News - Dermatology - March 11, 2013 Category: Dermatology Source Type: news

In Mouse Model, Small Peptide Ameliorates Autoimmune Skin Blistering Disease
Pemphigus vulgaris is a life-threatening autoimmune skin disease that is occurs when the body's immune system generates antibodies that target proteins in the skin known as desomogleins. Desmogleins help to form the adhesive bonds that hold skin cells together and keep the skin intact. Currently, pemphigus vulgaris is treated by long-term immune suppression; however, this can leave the patient susceptible to infection... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 10, 2013 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

In Vitro Pathogenicity Assay for Anti-desmoglein Autoantibodies in Pemphigus
We describe here two assays that measure the pathogenic strength of autoantibodies in blister formation: an in vitro dissociation assay using primary human epidermal keratinocytes to assess pathogenicity of anti-Dsg3 autoantibodies, and an alternative method whereby anti-Dsg3 and Dsg1 autoantibodies are injected into organ-cultured human skin specimen. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - December 19, 2012 Category: Molecular Biology Source Type: news